Relmada Therapeutics (RLMD) AI Stock Analysis

• Market Cap: $19.52M
• Dividend Yield: N/A
• Average Volume (3M): 192.70K
• Price to Earnings (P/E): ―
• Beta (1Y): 2.08
• Revenue Growth: N/A
• EPS Growth: 23.17%
• Country: US
• Employees: 17
• Sector: Healthcare
• Sector Strength: 41
• Industry: Biotechnology
• EPS (TTM): -0.30
• Shares Outstanding: 33,191,624
• 10 Day Avg. Volume: 162,025
• 30 Day Avg. Volume: 192,696
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: -0.04
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: <0.01
• 1Y Price Target: $1.00
• Price Target Upside: 75.44% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 1

• Rating: 41 Neutral
• Price Target: ―

Relmada Therapeutics' overall score reflects its high-risk, high-reward profile typical of biotechnology firms in developmental stages. The company's financial performance is weakened by zero revenue and significant cash burn, tempered by strong cash reserves. Strategic pipeline developments and recent acquisitions offer potential upside, but are countered by challenges such as discontinued projects and reliance on external financing. Technical analysis shows short-term momentum, but the overall outlook remains speculative.

Positive Factors

Clinical Trial Success

NDV-01 for high-grade non-muscle invasive bladder cancer showed an overall response rate of 85% and high-grade recurrence-free survival in patients with papillary disease of 83%.

Market Potential

Relmada announced in-licensing of Trigone's NDV-01 for treating NMIBC, which is seen as a multi-billion opportunity.

Safety and Administration

NDV-01 was well-tolerated with no treatment-related adverse events greater than grade 1.

Negative Factors

Development Prioritization

The company is re-evaluating further development of ‘P11 (novel psilocybin) as part of its prioritization efforts.

Pipeline Uncertainty

The company ended the year with $27M in cash, and additional data and updates from the pipeline are awaited before making any substantive comments regarding the pipeline assets.

Valuation Concerns

At this point, the product is not being added into the valuation, and the recommendation remains Market Perform.

Relmada Therapeutics Business Overview & Revenue Model

Company Description

Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that is in Phase 3 clinical trials for the adjunctive or monotherapy treatment of major depressive disorder in adults. The company was founded in 2004 and is headquartered in Coral Gables, Florida.

How the Company Makes Money

Relmada Therapeutics primarily generates revenue through strategic partnerships, collaborations, and funding related to the research and development of its pipeline therapies. As a clinical-stage company, Relmada does not yet have products on the market generating sales revenue. Instead, it relies on investments, grants, and milestone payments from partners who are interested in the potential of its drug candidates. These collaborations can involve licensing agreements or co-development arrangements, which provide financial support for the ongoing development of their therapies. The company's future revenue streams are expected to depend on the successful clinical trials and subsequent commercialization of its lead candidates, particularly if regulatory approvals are obtained.

Relmada Therapeutics Financial Statement Overview

Summary

Relmada Therapeutics is in a precarious financial state with no revenue and high research and development expenses leading to continuous losses. While the company benefits from strong cash reserves, the persistent negative cash flow emphasizes the need for successful product development to ensure sustainability.

Income Statement

Relmada Therapeutics has consistently reported zero revenue over the years, indicating that the company is still in the development stage, typical for biotech firms. The net income has been negative, showing significant losses, primarily due to high research and development expenses. There is no revenue growth, gross profit, or positive EBIT margin, which are critical for long-term sustainability.

Balance Sheet

The company's balance sheet shows adequate liquidity, with significant cash reserves compared to its liabilities, resulting in a negative net debt. However, the lack of revenue generation could pose a long-term risk if cash reserves are depleted without incoming revenue. The equity ratio is strong, but the absence of debt may limit financial leverage for expansion once products reach commercialization.

Cash Flow

Relmada Therapeutics has experienced negative operating and free cash flows due to ongoing operational expenses without revenue offset. The persistent negative free cash flow indicates dependency on external financing, which could be a concern if capital markets become less favorable. The cash flow situation highlights a need for strategic planning towards revenue generation.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00	0.00
Gross Profit	0.00	0.00	0.00	0.00	-1.26K	-3.75K
EBITDA	-70.11M	-79.98M	4.91M	-157.04M	-125.75M	-59.45M
Net Income	-67.81M	-79.98M	-98.79M	-157.04M	-125.75M	-59.46M
Balance Sheet
Total Assets	21.12M	45.82M	97.55M	152.91M	223.33M	118.19M
Cash, Cash Equivalents and Short-Term Investments	20.62M	44.91M	96.32M	148.32M	211.91M	117.09M
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00
Total Liabilities	5.17M	10.30M	12.19M	12.47M	15.06M	12.60M
Stockholders Equity	15.95M	35.52M	85.36M	140.44M	208.26M	105.58M
Cash Flow
Free Cash Flow	-49.92M	-51.76M	-51.66M	-103.80M	-91.87M	-27.81M
Operating Cash Flow	-49.92M	-51.76M	-51.66M	-103.80M	-91.87M	-27.81M
Investing Cash Flow	49.53M	51.56M	50.45M	19.73M	-54.12M	-34.45M
Financing Cash Flow	-335.11K	-40.34K	-98.46K	45.02M	187.94M	28.47M

Relmada Therapeutics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.57
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For RLMD, the sentiment is Negative. The current price of 0.57 is below the 20-day moving average (MA) of 0.61, below the 50-day MA of 0.65, and below the 200-day MA of 0.84, indicating a bearish trend. The MACD of -0.01 indicates Positive momentum. The RSI at 44.30 is Neutral, neither overbought nor oversold. The STOCH value of 21.74 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for RLMD.

Relmada Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	60 Neutral	HK$18.14B	5.30	-4.00%	3.33%	10.16%	-17.39%
IMRN	46 Neutral	$11.97M	―	-52.79%	―	82.77%	-87.95%
RLMD	41 Neutral	$19.52M	―	-175.12%	―	―	23.17%
CTXR	38 Underperform	$14.53M	―	-53.42%	―	―	18.73%
BTAI	37 Underperform	$41.18M	―	82.91%	―	-63.88%	77.72%
HOOK	37 Underperform	$10.31M	―	-105.79%	―	-82.54%	-12.53%
ATHA	36 Underperform	$15.18M	―	-103.80%	―	―	47.99%

Relmada Therapeutics Corporate Events

Relmada Therapeutics Announces Positive Phase 2 Study Results

On April 28, 2025, Relmada Therapeutics announced positive initial data from its Phase 2 study of NDV-01, a novel delivery formulation for treating non-muscle invasive bladder cancer, at the American Urology Association 2025 Annual Meeting. The study showed that 90% of patients achieved high-grade disease-free status, demonstrating strong clinical activity and supporting further development of NDV-01. The treatment was well tolerated with no significant adverse events, suggesting a promising future for NDV-01 as a potential class-leading therapy for NMIBC.

Spark’s Take on RLMD Stock

According to Spark, TipRanks’ AI Analyst, RLMD is a Neutral.

Relmada Therapeutics’ stock is currently speculative, characterized by significant financial challenges including zero revenue and high cash burn. While recent strategic acquisitions and pipeline developments offer potential for future growth, the current financial performance and valuation indicate high risk. Technical analysis suggests short-term momentum, but volatility remains a concern.

To see Spark’s full report on RLMD stock, click here.

Relmada Therapeutics Secures Exclusive License for NDV-01

On March 24, 2025, Relmada Therapeutics entered into an exclusive license agreement with Trigone Pharma for NDV-01, a novel sustained-release formulation of gemcitabine and docetaxel for treating Non-Muscle Invasive Bladder Cancer. This agreement grants Relmada worldwide rights, excluding India, Israel, and South Africa, and involves a $3.5 million upfront payment, potential milestone payments up to $200 million, and a 3% royalty on net sales. NDV-01 is expected to be a first-line therapy for NMIBC, offering significant clinical benefits, and its Phase 2 data will be presented at the American Urological Association meeting in April 2025.

Relmada Therapeutics Acquires Sepranolone for CNS Portfolio

Relmada Therapeutics has entered into an Asset Purchase Agreement with Asarina Pharma AB to acquire Sepranolone, a Phase 2b ready neurosteroid being developed for Tourette Syndrome and other compulsive disorders, for €3 million. This acquisition aligns with Relmada’s strategy to enhance its CNS disorder treatment portfolio, as Sepranolone has shown promising Phase 2a results, offering significant tic reduction and quality of life improvements without serious side effects, potentially positioning it as a first-line treatment for Tourette Syndrome.